The polyketide natural product Leptomycin B inhibits nuclear export mediated by the karyopherin protein chromosomal region maintenance 1 (CRM1). Here, we present 1.8-to 2.0-Å-resolution crystal structures of CRM1 bound to Leptomycin B and related inhibitors Anguinomycin A and Ratjadone A. Structural and complementary chemical analyses reveal an unexpected mechanism of inhibition involving covalent conjugation and CRM1-mediated hydrolysis of the natural products' lactone rings. Furthermore, mutagenesis reveals the mechanism of hydrolysis by CRM1. The nuclear export signal (NES)-binding groove of CRM1 is able to drive a chemical reaction in addition to binding protein cargos for transport through the nuclear pore complex.
The polyketide natural product Leptomycin B inhibits nuclear export mediated by the karyopherin protein chromosomal region maintenance 1 (CRM1). Here, we present 1.8-to 2.0-Å-resolution crystal structures of CRM1 bound to Leptomycin B and related inhibitors Anguinomycin A and Ratjadone A. Structural and complementary chemical analyses reveal an unexpected mechanism of inhibition involving covalent conjugation and CRM1-mediated hydrolysis of the natural products' lactone rings. Furthermore, mutagenesis reveals the mechanism of hydrolysis by CRM1. The nuclear export signal (NES)-binding groove of CRM1 is able to drive a chemical reaction in addition to binding protein cargos for transport through the nuclear pore complex.
exportin-1 | Xpo-1 | lactone hydrolysis | Michael addition | KPT inhibitor T he polyketide natural product Leptomycin B (LMB) has intrigued chemists and biologists with its highly complex structure, anticancer properties, and biological activity as an efficient and selective inhibitor of nuclear export mediated by the chromosomal region maintenance 1 protein (CRM1) (1) (2) (3) (4) (5) (6) (7) . Its frequent use as a cell biological tool has led to the discovery of hundreds of broadly functioning nuclear export cargos (2-4), which bind a hydrophobic groove of CRM1 through their nuclear export signals (NESs) (8) (9) (10) (11) . LMB is a 540-Da polyketide containing an α,β-unsaturated δ-lactone, two conjugated dienes, a β-hydroxy-ketone moiety, and a terminal carboxylate (Fig.  1A) . LMB binds covalently to Cys-528 in the human CRM1 ( Hs CRM1) NES-binding groove through a Michael reaction at its α,β-unsaturated δ-lactone moiety (Fig. 1B) (1) . Although LMB is predicted to occupy at least part of the groove (9, 11) , it is unclear how it interacts with CRM1, if it is an NES mimic, or if it changes the CRM1 groove conformation.
Results and Discussion
Overall Structures of Inhibitor-Bound CRM1 Complexes. We present the 1.8-to 2.0-Å-resolution crystal structures of LMB and related inhibitors Ratjadone A (RJA) (12, 13) and Anguinomycin A (AGA) (14) bound to the ternary complex of Saccharomyces cerevisiae CRM1 ( Sc CRM1), RanBP1, and human Ran•GppNHp (Table S1 ). CRM1-LMB complexes did not crystallize, whereas the CRM1-Ran-RanBP1 complex bound LMB and formed crystals in 1-2 d. The ternary protein complex was, therefore, used solely to obtain high-resolution crystals of LMB-bound CRM1. The overall structure of the LMB-bound complex is shown in Fig. 1C . We mutated Thr-539 of LMB-insensitive Sc CRM1 (equivalent to Cys-528 of Hs CRM1) to cysteine for covalent modification by inhibitors, and the mutant is named Sc CRM1*. Hs CRM1 and Sc CRM1 grooves differ in only a few residues (Fig.  1D) . Structure of the yeast groove with swapped human residues is virtually unchanged, thus validating the Sc CRM1* complex as a mimic of the human complex (SI Results and Discussion and Figs. S1 and S2 A and B).
CRM1 is composed of 21 tandem HEAT repeats (HEAT named after the proteins Huntingtin, Elongation factor 3, protein phosphatase 2A, and TOR1 kinase), each designated H1-H21 and containing a pair of antiparallel helices A and B. The NES-binding groove of CRM1 is located between HEAT repeats H11 and H12 (9) (10) (11) . The three inhibitor-bound structures are virtually identical (Cα rmsds of 0.2-0.3 Å), with inhibitors occupying ∼70% of the NES-binding groove (Fig. 1C) . LMB, AGA, and RJA each bury 738, 704, and 663 Å 2 of the groove, respectively. Overall structures of the inhibitor-bound Sc CRM1*-Ran-RanBP1 complexes are very similar to the previously reported Sc CRM1-Ran-RanBP1 structure (all residues Cα rmsds of 0.7-0.8 Å) (15) .
Conformational Plasticity of the CRM1 Groove. In the absence of inhibitors, the Sc CRM1* groove is closed as observed previously in the Sc CRM1-Ran-RanBP1 complex ( Fig. 2A , Fig. S2 C and D, and Table S2 ) (Cα rmsd is 0.3 Å for groove residues 521-605) (15) . However, the CRM1 grooves open to bind the lactone polyketide inhibitors ( Fig. 2A and Figs. S2 A and B and S3) (Cα rmsds of 0.8-1.0 Å for superpositions of groove residues 521-605). Interestingly, covalent conjugation is not strictly required for LMB binding or opening of the CRM1 groove, because the groove is also open in a complex of LMB with CRM1 that lacks the reactive cysteine ( Fig. S4 and Table S2 ). Each of the three inhibitor-bound CRM1 grooves adopts conformation that is intermediate between the closed groove of inhibitor-free Sc CRM1-Ran-RanBP1 (15) and the slightly wider grooves of NES-bound CRM1 (9-11) ( Fig. 2 A-C) (Cα rmsds of 0.8-1.1 Å for 85 groove residues). Conformational plasticity explains why computational modeling of LMB into a rigid NES-bound groove produced a model that is quite different from our crystal structures (14) (SI Results and Discussion).
Conformational differences between empty and inhibitor-and NES-bound grooves result from both helix reorientation ( Fig. 2 B and C) and rearrangements of a few sidechains, including Arg-543, Lys-545, Lys-548, Phe-572, Glu-582, and Phe-583 ( Fig. S2 A and C). When LMB is bound, groove residues Met-556 and Met-594 sidechains ( Hs CRM1 Met-545 and Met-583) also each rotate ∼90°away from the groove surface to deepen the groove, thus allowing the inhibitor to penetrate much deeper into the groove than the NES peptide ( Fig. 2C) (9) (10) (11) . LMB occupies the same space as four of five hydrophobic PKIα NES residues (ϕ0, ϕ1, ϕ2, ϕ3, and ϕ4) (Fig. 2C) (10) . Extensive inhibitor-NES overlap and inhibitor occupation of most of the groove suggest that LMB will displace most NES peptides, thus explaining its broad spectrum of nuclear export block.
Covalent Conjugation and CRM1-Mediated Hydrolysis. LMB, RJA, and AGA are all covalently conjugated to Cys-539 of Sc CRM1* ( Fig. 3 and Figs. S2 A and B and S3). Most strikingly, electron densities clearly show that, in each case, the lactone ring has been hydrolyzed to a hydroxy acid, although hydrolysis of α,β-unsaturated lactone compounds is disfavored at neutral pH (16) (Figs. 1B and 3 and Figs. S2A and S3 A and C) (MS data in Fig. 4A ). In fact, 1 H-NMR analysis of LMB at pH values 3, 5, 7, and 8.5 showed no detectable lactone hydrolysis; LMB hydrolysis only begins to be observable at pH 10.0 (Fig. 4B) . Therefore, without CRM1, less than 1% (limit of detection of NMR analysis) of LMB is hydrolyzed in our crystallization buffer of pH 6.6, suggesting that CRM1 stabilizes hydrolyzed lactone (Fig. 4B) . Furthermore, comparison of LMB and a chemically hydrolyzed LMB showed that the latter does not inhibit CRM1 (Fig. 4C) , suggesting that hydrolysis likely follows Michael addition. Consistent with this argument, Michael addition to LMB is more facile, because the β-carbon of its activated alkene is more electrophilic than the counterpart in the hydrolyzed LMB carboxylate.
LMB, AGA, and RJA bind the CRM1 groove through extensive electrostatic and hydrophobic interactions. The carboxyl groups of the hydrolyzed lactones or hydroxy acid moieties of LMB and AGA form salt bridges with Lys-548, polar interactions with the amide of Val-540, and long-range electrostatic interactions with Arg-543 ( Fig. 3 A and B) . The hydroxyl groups of the hydrolyzed lactones of LMB and AGA are near the Lys-579 sidechain, whereas that group in RJA adopts an alternative conformation, rotating ∼150°to hydrogen bond with Ala-552 and folding its carboxylate to the groove opening for a salt bridge with Lys-579 (Fig. 3C) . The polyketide chain of each inhibitor binds within the groove in a similar fashion, making numerous hydrophobic contacts to protein sidechains that also contact NESs (Fig.  3 ) (9) (10) (11) . With the exception of the β-hydroxy-ketone groups of LMB and AGA, almost every carbon atom of each inhibitor contacts CRM1. The terminal carboxylates of LMB and AGA make several electrostatic interactions with Lys-525 and His-569 at the bottom of the groove to provide a second electrostatic anchor at the opposite end of the inhibitors (Fig. 3 A and B) . The hydrolyzed lactone of LMB seems to be stabilized by Lys-548 and Lys-579. Four additional basic residues (Lys-541, Lys-542, Arg-543, and Lys-545) nearby could potentially reach into the groove near the hydrolysis site (Fig. 3A) . Electrostatic surface potential of the CRM1 groove is shown in Figs. S2B and S3 B and D. We mutated these basic residues and solved structures of five different LMBSc CRM1 mutants to look for effects in conjugation and lactone hydrolysis ( Fig. 5 A and B, Figs . S5, S6,  S7, and S8, and Tables S3 and S4) . We changed K548, K579, or both residues together [ Sc CRM1*(K548A), Sc CRM1*(K579A), and Sc CRM1*(K548E,K579Q)]; in all cases, LMB or RJA was conjugated to Cys-539, and the lactone ring was hydrolyzed ( Fig.  5A and Figs. S5, S6, and S8 A and B). When Lys-548 is mutated, the Arg-543 sidechain moves into the groove, substituting for the missing lysine (Fig. 5A) . Thus, it seems that only one of Arg-543, Lys-548, and Lys-579 or even simply, a general positive charge near the lactone may be sufficient to drive ester hydrolysis (Fig.  3A and Figs. S2B and S3 B and D). We tested this hypothesis by mutating Arg-543, Lys-548, and Lys-579 in mutant Sc CRM1* (R543S,K548E,K579Q) and removing all positively charged residues near the reaction site in mutant Sc CRM1*(K541Q, K542Q,R543S,K545Q,K548Q,K579Q). Structures of both mutants showed closed lactone rings conjugated to Cys-539, suggesting that we had trapped a covalently linked saturated lactone intermediate ( Fig. 5B and Figs. S7 and S8C). Electron densities of the closed-ring lactone intermediate are shown in Fig. S7 A and C. The presence of any one of Arg-543, Lys-548, or Lys-579 seems sufficient to drive LMB hydrolysis on conjugation of the α,β-unsaturated lactone ring to CRM1. These three basic residues are also important for NES binding (Fig. S9) . Structures of the CRM1 mutants conjugated to closed saturated lactone intermediates ( Fig. 5B and Fig. S8C ) also suggest that conjugation alone is insufficient for lactone hydrolysis. Consistent with this argument, we observed that only a small amount (<10%) of DTTconjugated LMB alone is hydrolyzed after 26 h ( Fig. S10 and Table S5 ).
Superposition of the LMB-bound grooves of Sc CRM1* and Sc CRM1*(R543S,K548E,K579Q) informed on potential nucleophile and stabilization of the tetrahedral intermediate of hydrolysis (Fig. 5C) . A bound water molecule is located 3.1 Å from the carbonyl carbon of the superimposed saturated lactone intermediate. Its almost perpendicular position to the plane of the ester is optimal for nucleophilic attack on the carbonyl carbon (Figs. 1B and 5 C and D). Arg-543, Lys-548, and Lys-579 are poised to form an oxyanion hole that could stabilize the resulting anionic tetrahedral intermediate and lower the energy barrier for hydrolysis. Lys-548 and Lys-579 sidechains could approach as close as 2.5 Å to the carbonyl carbon of the conjugated lactone, whereas Arg-543 may get within 4 Å of the group. The three basic residues may also contribute to hydrolysis through stabilization of the final anionic product. Chemically hydrolyzed LMB slowly reverses back to ring-closed LMB in the absence of CRM1 (Fig.  S11 ). Although not commonly observed, a similar hydrolysis reaction was recently shown to occur with a cyclic imide, which is formed by Michael addition of a cysteine to a succinimide ring, in a positively charged binding site of an engineered antibody (17) .
Structural Comparison with KPT-185 and KPT-251 Inhibitors. KPT-185 and KPT-251 (Karyopharm Therapeutics, Natick, MA) are members of a new class of drug-like small-molecule compounds that were designed to bind the NES groove of CRM1. We recently reported crystal structures of Sc CRM1*-Ran-RanBP1 complexes bound to the prototype compounds KPT-185 and KPT-251, respectively (molecular masses of 353.3 and 375.2 Da, respectively) ( Fig. 6A) (18, 19) . The KPT inhibitors share a trifluoromethyl phenyl triazole scaffold. Both compounds also contain Michael acceptors, an isopropyl acrylate in KPT-185, and an alkyl oxadiazole in KPT-251 for covalent conjugation to the reactive cysteine of CRM1. Because the two KPT compounds bind CRM1 very similarly, we compare only CRM1-bound LMB with KPT-185, as the latter also contains a reactive enone moiety.
Like LMB, KPT-185 binds in the NES groove, and the reactive alkene of its enone forms a covalent bond with Cys-539 of Sc CRM1*. However, although LMB fills most of the groove, the smaller KPT-185 occupies only ∼40% of the groove. Much of the space filled by the polyketide chain of LMB or by the PKIα NES helix remains unoccupied in the KPT-185-bound groove ( Fig. 6A ) (18) . Instead, the isopropyl acrylate portion of KPT-185 sits in the narrow channel above Cys-539 that is not occupied by LMB. Unlike LMB, which binds CRM1 through extensive electrostatic and hydrophobic interactions, KPT-185 binds almost solely through hydrophobic interactions.
KPT-185 is not hydrolyzed when bound to CRM1 ( Fig. 6 A and B) (18) . Its isopropyl acrylate binds deeper in the CRM1 groove than either the intact or opened lactone of LMB. The closed-ring LMB lactone is positioned near the opening of the NES groove with an ordered water molecule nearby as the potential nucleophile (Figs. 5C and 6B). In contrast, the carbonyl carbon of the KPT-185 enone is close to the floor of the groove surrounded by hydrophobic sidechains (Fig. 6 A and B) . In addition to the lack of potential nucleophiles in this hydrophobic environment, the intact KPT-185 isopropyl acrylate (potential hydrolysis substrate) likely makes many more contacts with CRM1 than the cleaved hydrolysis product. This situation contrasts with LMB, where the hydrolysis product forms many more interactions with CRM1 than the lactone substrate. Thus, in the case of KPT-185, substrate stabilization may further decrease the likelihood of enone hydrolysis.
Lactone Hydrolysis Decreases Reversibility of Covalent Conjugation.
Lactone hydrolysis of LMB results in electrostatic anchoring of the inhibitor at both termini of the CRM1 groove, and the anionic hydrolysis product complements a highly basic pocket in the groove, possibly contributing significant additional binding energy beyond covalent conjugation at the single cysteine site ( Fig. 3A and Fig. S2B ). Furthermore, by analogy with other Michael addition reactions, reversibility of the conjugate addition of cysteine should be kinetically controlled, with deprotonation of the inhibitor α-proton as the rate-determining step (Fig. 5D ). The α-proton of the hydrolyzed (carboxylate) inhibitor should be appreciably less acidic than the α-proton of the lactone (20, 21) . Thus, ring opening should enable lactone-based inhibitors to attach more persistently to CRM1 than analogous inhibitors without this capability.
We compared the stability of LMB conjugation with Sc CRM1* vs. mutant Sc CRM1*(K541Q,K542Q,R543S,K545Q,K548Q, K579Q), which does not hydrolyze LMB, to test the effect of lactone hydrolysis on the reversibility of covalent conjugation ( Fig. 6 C and D and Fig. S12 ). LMB-conjugated proteins were either dialyzed or treated with 20 mM DTT to remove unbound inhibitors, and the extent of LMB conjugation was determined by a CRM1 inhibition assay using immobilized NES. LMB persistently bound and fully inhibited Sc CRM1*, even after dialysis and DTT treatment, indicating no detectable deconjugation. Interestingly, the hydrolysis incompetent CRM1 mutant showed decreased inhibition after removal of unbound inhibitor (Fig. 6 C  and D) , suggesting that ∼20-30% of previously bound LMB is no longer conjugated to CRM1 (Fig. S12) . Similarly, KPT-185, which contains a reactive enone but is not hydrolyzed by CRM1, also significantly decreased inhibition after dialysis or DTT treatment ( Fig. 6 C and D) ; ∼40-60% of previously bound KPT-185 seems to be no longer conjugated to CRM1 (Fig. S12) , suggesting that the inhibitor binds CRM1 in a slowly reversible fashion. These results support the notion that lactone hydrolysis decreases reversibility of the Michael addition to enable persistent binding of LMB to CRM1. A similar protein-driven hydrolysis of a succinimide ring that is conjugated to an engineered antibody also resulted in increased stability of the protein conjugate (17) .
Timescale of CRM1-Mediated Hydrolysis of LMB. The main evidence for hydrolysis of LMB by CRM1 derives from LMBSc CRM1*-RanRanBP1 crystals that were typically frozen in liquid nitrogen within 24 h of LMB addition to CRM1. Because we have been unable to analyze the kinetics of lactone hydrolysis of the LMB-CRM1 conjugate in solution, our resolution in quantifying the rate of this process is limited by the timescale of crystallization. Thus, we conservatively place the timescale of this reaction in the range of hours, although it could be significantly faster. Lactone or enone hydrolysis is not crucial for LMB or KPT-185 to inhibit NES recognition by CRM1, but CRM1-mediated lactone hydrolysis seems to be significant for long-lived inhibition by LMB and other α,β-unsaturated lactone polyketide inhibitors (Fig. 6 C and D) . Such persistent inhibition may contribute to the long-lived clinical toxicity previously observed for LMB, even several days after removal of the drug (5).
Conclusion
In summary, LMB is targeted to the NES-binding groove of CRM1 through covalent conjugation to a reactive cysteine residue (Fig. 5D ). Subsequent lactone hydrolysis by CRM1 optimizes LMB-CRM1 interactions and irreversibility of conjugation and thus, inhibitor potency. A karyopherin protein, which normally binds transport cargos and other protein ligands, has been shown here to drive a chemical reaction. An intriguing question to address in the future is whether CRM1 has analogous catalytic activities with endogenous biological substrates other than the α,β-unsaturated lactone polyketide inhibitors. 
Materials and Methods
Detailed materials and methods are described in SI Materials and Methods. Briefly, (i) Sc CRM1* or mutant Sc CRM1*(K541Q,K542Q,R543S,K545Q,K548Q,K579Q) were incubated with LMB or KPT-185 to achieve full CRM1 inhibition before dialysis of the samples (C) or treatment with 20 mM DTT (D) to remove excess unbound inhibitor. The extent of CRM1 inhibition was determined using pulldown inhibition assays with immobilized GST-NES, and the proteins were separated by SDS/PAGE and visualized with Coomassie staining. (Fig. 1D) . Almost all CRM1 residues involved in NES and inhibitor binding are strictly conserved. Nevertheless, the small difference in sequence of residues that line the (Fig.  4C) , and third, CRM1-mediated nuclear export in the CRM1T539C S. cerevisiae strain, where Thr-539 of Sc CRM1 is mutated to cysteine, is similarly sensitive to LMB as mammalian cells (1) . MS results of Sc CRM1* and LMBSc CRM1* provide support for hydrolyzed LMB conjugated to CRM1 that is independent of our crystallographic findings (Fig. 4A) . 13 C-NMR analysis of CRM1-bound LMB is hindered by the current unavailability of 13 C-LMB and the LMB-producing streptomyces strain (2) in the public domain.
Supporting Information
Comparison of Computational Model and Crystal Structure of the CRM1-LMB Complex. LMB and CRM1 are both flexible molecules, although previous work suggested otherwise. The LMBbound groove is narrower and deeper than the NES-bound groove as a result of helix and sidechain reorientations. Therefore, it is not surprising that computational modeling of LMB into the wider and shallower NES-bound groove produced a model that is quite different from our crystal structures (3). LMB molecules in the model and our structures bind the CRM1 groove in grossly similar directions. However, beyond this trivial similarity, their modes of interaction with CRM1 differ significantly. These differences are largely because of conformational changes of the CRM1 groove and also hydrolysis of the LMB lactone by CRM1, which were revealed entirely and unexpectedly by our structures.
Differences between a previously reported computational model (3) and our crystal structure are as follows. (i) LMB bound as a lactone in the computational model, whereas the crystal structure showed that the lactone ring of LMB was hydrolyzed (Fig. 3A) . Lactone hydrolysis could not have been predicted by computational modeling. (ii) LMB in the computational model is conjugated to CRM1 in the S configuration. In the X-ray structures, LMB (both lactone and hydroxy acid forms) bound in the R configuration, which is accommodated by numerous interactions in a conformationally rearranged groove (Fig. 3A) . (iii) The polyketide portion of LMB is quite flexible because of many rotatable C-C bonds, thus making modeling difficult and unreliable (3). This problem is further compounded by CRM1 groove plasticity (Fig. 2) . As a result, the modeled LMB is mostly straight (3), whereas LMBs in our crystal structures make two ∼90°turns to penetrate deep into the groove (Figs. 2C and 3A) . (iv) The different orientations and chemical structures of LMB in the computational and X-ray models placed chemical groups in different vertical positions along the grooves. In the computational model, the hydrophobic position Φ1 of NES overlaps with LMB C31, NES Φ2 overlaps with LMB C29, and NES Φ3 overlaps with LMB C27 (3). The X-ray structures are very different, with NES Φ1 overlapping with LMB C32, NES Φ2 overlapping with LMB C28, and NES Φ3 overlapping with C4 and C5 of the hydroxy acid of LMB (Fig. 2C) .
SI Materials and Methods
Cloning, Expression, and Protein Purification.
Hs
Ran was cloned into the pET18 vector.
Sc

CRM1 and
Sc
RanBP1 were cloned into a pGEX-4t-3-based expression vector with a tobacco etch virus protease-cleavable N-terminal GST tag. Residues 377-413 of Sc CRM1 were removed as previously described (4), and Thr-539 was mutated to cysteine to generate the inhibitor-accessible (Tables S2-S4) were generated by site-directed mutagenesis using PCR.
CRM1,
Sc
RanBP1, and
Hs
Ran were expressed separately in Escherichia coli BL-21 (DE3) after induction with 0.5 mM isopropyl β-D-1-thiogalactopyranoside for 10 h at 25°C. The three proteins were purified separately. GST-
Sc
CRM1 and GSTSc
RanBP1 were purified by glutathione Sepharose (GE Healthcare) affinity chromatography, cleaved off the beads with TEV protease, and further purified by gel filtration chromatography in buffer containing 10 mM Tris, pH 7.5, 100 mM NaCl, and 5 mM MgCl 2 . His-tagged
Hs
Ran was purified by affinity chromatography using Ni-NTA beads (QIAGEN), eluted with buffer containing 20 mM Tris, pH 7.5, 10% glycerol, 200 mM Imidazole, and 200 mM NaCl, and further purified by gel filtration in buffer containing 10 mM Tris, pH 7.5, 100 mM NaCl, and 5 mM MgCl 2 .
Ran was loaded with nucleotide analog 5′-Guanylyl imidodiphosphate (GppNHp) as previously described (5).
Sc
CRM1*-
Hs
Ran-
Sc
RanBP1 complexes were obtained by mixing the three proteins at a 1:2:1.5 molar ratio followed by gel filtration chromatography. The purified protein complexes were then mixed with CRM1 inhibitors (Enzo Life Sciences) at a 1:2 molar ratio. The Sc CRM1(T539S)-Hs RanSc RanBP1 complex was mixed with LMB at a 1:10 molar ratio to achieve maximum noncovalent binding of the inhibitor.
Crystallization, Data Collection, Structure Determination, and Refinement. Crystals of the CRM1 inhibitor complexes grew in 1-2 d in conditions similar to those conditions used by Koyama and Matsuura (4) (reservoir solution 18% PEG3350, 200 mM ammonium nitrate, 100 mM Bis·Tris, pH 6.6). Crystallization solutions were supplemented with 20% (vol/vol) glycerol to cryoprotect the crystals. X-ray diffraction data were collected at beamline 19ID, Advanced Photon Source, Argonne National Laboratory (Tables S1-S4 ). The structures were solved using the molecular replacement program MolRep (6) and the coordinates of 
RanBP1 complex is present in each asymmetric unit. The resulting models and electron density maps were examined with the program COOT (7) . Several cycles of model rebuilding and refinement using the program Refmac5 (8) led to convergence. Translation/ Libration/Screw refinement was used in the refinement process (9) . Ramanchandran statistics were calculated using the CCP4 program Procheck (10).
Chemical Analysis of LMB Hydrolysis Products by NMR and LC-MS.
1 H-NMR spectra of LMB at pH values of 3.0, 5.0, 7.0, 8.5, and 10 were measured in 30% CD 3 OD/D 2 O at 600 MHz. LMB was dissolved in D 2 O buffer that mimics the crystallization buffer (10 mM Bis·Tris, pH 6.6, 100 mM ammonium nitrate, 5% PEG, 1 mM Tris, pH 7.5, 50 mM sodium chloride, 2.5 mM magnesium acetate). Data were acquired 10 min after pH adjustment. LC-MS analysis of LMB + DTT in buffer and LMB in buffer (no DTT) were analyzed by LC-UV-MS using a Phenomenex C18 Luna HPLC column (4.6 × 100 mm) with a solvent gradient from 90:10 H 2 O:CH 3 Intact Protein Mass Determination. The modification reaction for MS analysis was carried out by incubating Sc CRM1* with LMB at room temperature for 10 min. The pH of the reaction solution was then lowered using 1% trifluoroacetic acid (TFA) solution to a final concentration of 0.1%, and the sample was injected immediately for trapping and MS analysis. In-line desalting was achieved using a reversed phase trap and self-packed with PO-ROS R1 20 μm 4,000-Å media (Applied Biosystems). Proteins were captured by the trap in 100% water and 0.1% formic acid and eluted in 50% acetonitrile, 50% trifluoroethanol, and 0.5% formic acid using a 5-μL/min flow rate delivered by a syringe pump. All analyses were performed using a 6540 Ultra HighDefinition Accurate-Mass Q-TOF mass spectrometer equipped with a Jet Stream ESI source (Agilent Technologies). Data were acquired in 4-GHz high-resolution mode with m/z range of 700-3,200 and a cycle time of 1.0 s. Data were then analyzed using the Maximum Entropy deconvolution algorithm from Agilent, which generates average masses of the target proteins by transforming the m/z raw spectrum into a zero-charge mass spectrum in Dalton units. Two MS experiments are shown in Fig. 4A . There is no obvious difference in the conditions for these two experiments. We suspect that LMB hydroxy acid is unstable in MS conditions and tends to cyclize at the low pH or gas phase ionization conditions of the experiment. The larger mass for the modification in Fig. 4A , Left implies the presence of some higher-molecular weight LMB hydroxy acid. The expected molecular mass for the LMB hydroxy acid is 558 Da. The observed molecular mass increase of 555 Da may be caused by a mixed population of LMB hydroxy acid and lactone, which cannot be resolved by MS of a 120-KDa protein. Most of the LMB hydroxy acid has recyclized in the right panel.
LC-MS/MS Analysis. A molar ratio of 1:2
Sc CRM1*:LMB samples was separated by SDS/PAGE and stained with Coomassie blue. The excised gel bands were chopped into 1-mm 3 cubes and ingel-digested using elastase. Coomassie blue stain was removed after 30 min incubation at 37°C in 50 mM triethylammonium bicarbonate/acetonitrile (1:1; vol/vol), and the gel pieces were dehydrated with acetonitrile at room temperature followed by reduction/alkylation using DTT and iodoacetamide. The gel pieces were then dehydrated and rehydrated again with solution containing elastase for overnight digestion at 37°C. Peptides were extracted using 30 min incubation at 37°C with extraction buffer (50% acetonitrile and 3.3% TFA), and salts were removed using the Oasis HLB μElution plate (Waters) before LC-MS/MS analysis. 1D LC was performed on an Ultimate 3000 nano HPLC system (Dionex) using reverse-phase ReproSil-Pur C18-AQ 1.9-μm resin column (Dr. Maisch GmbH). Separation of peptides was carried out at 400 nL/min by a 60-min linear gradient of 1-41% acetonitrile in 0.1% formic acid. Column temperature was raised and maintained at 70°C using a butterfly heater (Phoenix S&T, Inc.). MS analyses were performed on a Q Exactive instrument (Thermo Electron) using a data-dependent top20 method, with the full MS scans acquired at 70,000 resolution (at m/z 200) and MS/MS scans acquired at 17,500 resolution (at m/z 200). Underfill ratio was set at 0.3%, with a 3 m/z isolation window and fixed first mass of 100 m/z for the MS/MS acquisitions. The charge exclusion was applied to exclude the unassigned and charge 1 species, and dynamic exclusion was used with a duration of 15 s. Peptide coverage of Sc CRM1* was excellent at 90%, but the LMB-modified peptide was not identified. We detected only the unmodified peptide, although LMB was added in molar excess under conditions where we see complete inhibition of NES binding. We suspect that LMB conjugation is unstable after the binding site is destroyed by proteolysis, the modification does not survive MS ionization intact, and/or LMB modification drastically affects fragmentation, preventing identification.
Chemical Hydrolysis of LMB. LiOH (50 μL) in tetrahydrofuran (THF)/H 2 O (10 μg LiOH, 3.0 μL THF, 0.5 μL H 2 O) was added to 405 μg LMB in 200 μL THF. The mixture was stirred at room temperature under an N 2 atmosphere for 3 h. The hydrolysate was neutralized with HCl, diluted with water, subjected to a C 18 SEP-PAK (0.5 × 1.0 cm; Waters), and eluted with water followed by methanol. The elution was analyzed by LC-MS and purified by RP-HPLC (Phenomenex Luna, Phenyl-Hexyl; 5 mm, 250 × 10.0 mm, UV = 210 nm, 2.5-mL/min flow rate) using a gradient solvent system from 60% to 99% CH 3 CN (0.1% formic acid) over 30 min to yield the desired product (300 μg, t R = 10.5 min). electrospray ionization (ESI)-MS:
In Vitro NES-Binding and Inhibition Assays. To assess CRM1-NES interactions or CRM1 inhibition, either CRM1 proteins or inhibitor-CRM1 complexes were incubated with 10 μg immobilized GST-MVM-NS2 NES in a total volume of 100 μL for 30 min at 4°C. After extensive washing with buffer containing 50 mM Tris, pH 7.5, 110 mM potassium acetate, 20% glycerol, 1 mM EGTA, 2 mM magnesium acetate, and 2 mM DTT, bound proteins were separated by SDS/PAGE and visualized by Coomassie staining. To compare the potency of LMB or chemically hydrolyzed LMB, 120 μg purified Hs CRM1 or Sc CRM1* were incubated with 20 μM of either LMB or chemically hydrolyzed LMB in total volumes of 100 μL for 10 min at 4°C and then added to immobilized GST-MVM-NS2 NES for the binding assays above. To assess the reversibility of inhibitor conjugation, 2 nmol either Sc CRM1* or Sc CRM1* (K541Q,K542Q,R543S,K545Q,K548Q,K579Q) were mixed with 4 nmol LMB or 10 nmol KPT185 in total volumes of 200 μL. Triplicate samples were (i) used as controls of fully inhibited CRM1 and subjected immediately to CRM1 inhibition assays (above), (ii) dialyzed against buffer containing 10 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl 2 , and 2 mM DTT for 24 h at 25°C, or (iii) treated with 20 mM DTT at 25°C for 24 h. CRM1 inhibition assays were then performed using immobilized GST-MVM-NS2 NES and Hs Ran as described above. To compare the intensities of the different CRM1 bands of SDS/ PAGE gels and estimate the extent of CRM1 deconjugation, we scanned the dried gels with a desktop scanner (Epson V300) and processed images with the ImageJ software (intensity inverted, background subtracted). The intensity of each band plus three background sites were measured by drawing a fixed shape closely surrounding the band and integrating the densities. Band intensities were corrected for background and the slightly different amounts of GST-NES in each lane. GST-NES band intensities of lanes 1-5 were normalized to the band intensity of lane 1, GST-NES band intensities of lanes 6-8 were normalized to the band intensity of lane 6, and the respective CRM1 band intensities were corrected with the normalization factors. The same gels were scanned three times, and the mean corrected CRM1 band intensities and errors were plotted on histograms in Fig. S12 . CRM1*(K541Q,K542Q,R543S,K545Q,K548Q,K579Q) was incubated with LMB or KPT-185 to achieve full CRM1 inhibition before dialysis of the samples (A) or treatment with 20 mM DTT (B) to remove excess unbound inhibitor. The extent of CRM1 inhibition was determined using pull-down inhibition assays with immobilized GST-NES, and the proteins were separated by SDS/PAGE and visualized with Coomassie staining. The gels shown here are identical to those gels in Fig. 6 C and D. Scanned images of the dried gels were processed with the ImageJ software. The intensity of each CRM1 is corrected for the slightly different intensities of the GST-NES bands (lane 1 is the reference for lanes 1-5; lane 6 is the reference for lanes [6] [7] [8] . The gel was scanned three times, and average intensities and errors of the CRM1 bands were plotted on histograms. In the dialysis experiment (A), CRM1 band intensities in lanes 3 and 5 appear to be ∼10% and ∼48%, respectively, compared with the intensity in lane 1. The CRM1 band intensity in lane 8 is ∼41% compared with the reference in lane 6. In the DTT experiment (B), the CRM1 band intensities in lanes 3 and 5 appear to be ∼11% and ∼70%, respectively, compared with the intensity in lane 1. The CRM1 band intensity in lane 8 is ∼30% compared with the reference in lane 6. 
